NEW YORK (GenomeWeb News) - Osmetech said today it has exclusively licensed a molecular biomarker from Marshfield Clinic, a clinical and research facility in western Wisconsin, that it plans develop into a genetic test for determining appropriate warfarin doses.
Osmetech plans to develop, manufacture, and sell a genetic test based on the biomarker. Osmetech CEO James White said the biomarker will be used on the company’s XT-8 platform.
"We are excited to add this new SNP to our warfarin product which is due to be submitted later this year to the US Food and Drug Administration,” White said in a statement. “The marker provides additional information to improve the dosage accuracy over any other product on the market."
Osmetech said it plans to market the product in the first half of 2008.
Financial terms of the agreement were not released.